ArticleMolecular neuropsychiatry2019
Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles.
Article in Molecular neuropsychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Efficacy of non-invasive brain stimulation for post-stroke sleep disorders: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Targeting α5-GABAA receptors to restore dopamine system function in a translationally relevant model of perimenopausal psychosis.Psychopharmacology · 2026Article
- Enantiomer-specific modulation of GABAPsychopharmacology · 2026Article
- Development of Novel Pegylated Imidazobenzodiazepines Targeting α5 GABAA Receptors for Anxiety: A Comparative Prodrug and Metabolite Study.ACS chemical neuroscience · 2026Article
- The role of GABANeuroscience and biobehavioral reviews · 2026Review
- A Comparison of Positive and Negative Allosteric Modulators of α5-Containing GABABiological psychiatry · 2026Review
- Behavioral Domain-Specific Effects of Positive Modulation of α5 and α6 GABAPharmacology research & perspectives · 2026Article
- A Novel Polygenic Risk Score Indexing Somatostatin-Expressing Inhibitory Neurons Predicts Somatostatin-Expressing Cell Proportions and Severity of Symptoms in Late-Life Depression.Biological psychiatry global open science · 2026Article
- Eukaryotic initiation factor 4E: a key factor of traumatic stress-induced depression-related cognitive decline at different age.Translational psychiatry · 2026Article
- GABADrug design, development and therapy · 2026Review
- Intranasal Insulin Mitigates Memory Impairment and Neuroinflammation in a Mouse Model of Hippocampal Aging.Pharmacology research & perspectives · 2025Article
- Preclinical evidence for a novel pharmacotherapeutic approach for treating benzodiazepine addiction.Translational psychiatry · 2025Article
- Chronic α5-GABA-A Receptor Potentiation Promotes Mouse Adult Hippocampal Neurogenesis.Hippocampus · 2025Article
- Parenteral Nanoemulsion for Optimized Delivery of GL-II-73 to the Brain-Comparative In Vitro Blood-Brain Barrier and In Vivo Neuropharmacokinetic Evaluation.Pharmaceutics · 2025Article
- Electroencephalography Biomarkers of α5-GABA Positive Allosteric Modulators in Rodents.Biological psychiatry global open science · 2025Article
- Decoding the structural and functional diversity of GABAFrontiers in pharmacology · 2025Review
- Cognitive Dysfunction in the Addictions (CDiA): protocol for a neuron-to-neighbourhood collaborative research program.Frontiers in psychiatry · 2025Article
- Therapeutic dose prediction of α5-GABA receptor modulation from simulated EEG of depression severity.PLoS computational biology · 2024Article
- Effects of chronic stress on cognitive function - From neurobiology to intervention.Neurobiology of stress · 2024Review
- Large-Scale Mechanistic Models of Brain Circuits with Biophysically and Morphologically Detailed Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Altered gamma-aminobutyric acid (GABA) function is consistently reported in psychiatric disorders, normal aging, and neurodegenerative disorders and reduced function of GABA interneurons is associated with both mood and cognitive symptoms. Benzodiazepines (BZ) have broad anxiolytic, but also sedative, anticonvulsant and amnesic effects, due to nonspecific GABA-A receptor (GABAA-R) targeting. Varying the profile of activity of BZs at GABAA-Rs is predicted to uncover additional therapeutic potential. We synthesized four novel imidazobenzodiazepine (IBZD) amide ligands and tested them for positive allosteric modulation at multiple α-GABAA-R (α-positive allosteric modulators), pharmacokinetic properties, as well as anxiolytic and antidepressant activities in adult mice. Efficacy at reversing stress-induced or age-related working memory deficits was assessed using a spontaneous alternation task. Diazepam (DZP) was used as a control. Three ligands (GL-II-73, GL-II-74, and GL-II-75) demonstrated adequate brain penetration and showed predictive anxiolytic and antidepressant efficacies. GL-II-73 and GL-II-75 significantly reversed stress-induced and age-related working memory deficits. In contrast, DZP displayed anxiolytic but no antidepressant effects or effects on working memory. We demonstrate distinct profiles of anxiolytic, antidepressant, and/or pro-cognitive activities of newly designed IBZD amide ligands, suggesting novel therapeutic potential for IBZD derivatives in depression and aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.